Neurocrine CEO Kevin Gorman to retire after 32-year run; Bluebird picks up fifth CFO in three years

Af­ter more than three decades at Neu­ro­crine, CEO Kevin Gor­man will re­tire lat­er this year, hand­ing the reins of the $13 bil­lion neu­ro­science drug­mak­er over …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

CrowdStrike outage hits US hospitals

CrowdStrike, a growing cybersecurity firm, unwittingly triggered a massive IT outage on Friday, disrupting businesses, including healthcare, after issuing what was supposed to be a routine software

Read More »